{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:15:49Z","timestamp":1792617349432,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This cross-sectional study aimed to investigate the association between plasma homocysteine (Hcy) and chronic kidney disease (CKD) in US patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used data from the 2003\u20132006 National Health and Nutritional Examination Surveys (NHANES). CKD was defined as an estimated glomerular filtration rate\u2009&lt;\u200960\u2009ml\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      and\/or urinary albumin-creatine ratio\u2009\u2265\u20093\u2009mg\/mmol.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 1018 patients with T2DM. The mean Hcy value was 10.2\u2009\u00b1\u20094.6\u2009\u03bcmol\/L. Among the patients, 417 (40.96%) had hyperhomocysteinemia (HHcy) and 480 (47.15%) had CKD. The Hcy level was higher in patients with CKD than in those without CKD. Compared to patients with normal Hcy, those with HHcy were older and had worse renal function. After full multivariate adjustment, HHcy was positively associated with the risk of CKD in US patients with T2DM (OR, 1.17; 95% CI, 1.11\u20131.22;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001), which for women was 1.15 (95% CI, 1.08\u2009~\u20091.23;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) and for men was 1.18 (95% CI, 1.1\u2009~\u20091.27;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HHcy was independently associated with CKD in patients with T2DM. Further prospective studies are warranted to investigate the effect of Hcy on CKD in patients with T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-022-03045-6","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T10:38:49Z","timestamp":1672483129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Relationship between plasma homocysteine and chronic kidney disease in US patients with type 2 diabetes mellitus: a cross-sectional study"],"prefix":"10.1186","volume":"23","author":[{"given":"Zilong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"3045_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"3045_CR2","doi-asserted-by":"publisher","unstructured":"Shubrook JH, Neumiller JJ, Wright E. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. Postgrad Med. 2021:1\u201312. https:\/\/doi.org\/10.1080\/00325481.2021.2009726.","DOI":"10.1080\/00325481.2021.2009726"},{"key":"3045_CR3","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s13300-021-01050-w","volume":"12","author":"NS Skolnik","year":"2021","unstructured":"Skolnik NS, Style AJ. Importance of early screening and diagnosis of chronic kidney disease in patients with type 2 diabetes. Diabetes Ther. 2021;12:1613\u201330. https:\/\/doi.org\/10.1007\/s13300-021-01050-w.","journal-title":"Diabetes Ther"},{"key":"3045_CR4","doi-asserted-by":"publisher","first-page":"107834","DOI":"10.1016\/j.jdiacomp.2020.107834","volume":"35","author":"E Muzurovi\u0107","year":"2021","unstructured":"Muzurovi\u0107 E, Kraljevi\u0107 I, Solak M, Dragni\u0107 S, Mikhailidis DP. Homocysteine and diabetes: role in macrovascular and microvascular complications. J Diabetes Complicat. 2021;35:107834. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107834.","journal-title":"J Diabetes Complicat"},{"key":"3045_CR5","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1161\/01.str.0000223048.70103.f1","volume":"37","author":"LB Goldstein","year":"2006","unstructured":"Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association\/American Stroke Association stroke council: cosponsored by the atherosclerotic peripheral vascular disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology council; nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:1583\u2013633. https:\/\/doi.org\/10.1161\/01.str.0000223048.70103.f1.","journal-title":"Stroke."},{"key":"3045_CR6","doi-asserted-by":"publisher","first-page":"174168","DOI":"10.1016\/j.ejphar.2021.174168","volume":"905","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, Wang L, Si X, et al. Current progress on the mechanisms of hyperhomocysteinemia-induced vascular injury and use of natural polyphenol compounds. Eur J Pharmacol. 2021;905:174168. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174168.","journal-title":"Eur J Pharmacol"},{"key":"3045_CR7","doi-asserted-by":"publisher","first-page":"CD006612","DOI":"10.1002\/14651858.CD006612.pub5","volume":"8","author":"AJ Mart\u00ed-Carvajal","year":"2017","unstructured":"Mart\u00ed-Carvajal AJ, Sol\u00e0 I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612. https:\/\/doi.org\/10.1002\/14651858.CD006612.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"3045_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4103\/jrpp.jrpp_75_21","volume":"10","author":"S Badri","year":"2021","unstructured":"Badri S, Vahdat S, Seirafian S, Pourfarzam M, Gholipur-Shahraki T, Ataei S. Homocysteine-lowering interventions in chronic kidney disease. J Res Pharm Pract. 2021;10:114\u201324. https:\/\/doi.org\/10.4103\/jrpp.jrpp_75_21.","journal-title":"J Res Pharm Pract"},{"key":"3045_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40620-019-00618-x","volume":"32","author":"E Cohen","year":"2019","unstructured":"Cohen E, Margalit I, Shochat T, Goldberg E, Krause I. The relationship between the concentration of plasma homocysteine and chronic kidney disease: a cross sectional study of a large cohort. J Nephrol. 2019;32:783\u20139. https:\/\/doi.org\/10.1007\/s40620-019-00618-x.","journal-title":"J Nephrol."},{"key":"3045_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E Elm","year":"2007","unstructured":"Elm E, Altman DG, Egger M, Pocock SJ, Gatzsche PC, Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"key":"3045_CR11","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089\u2013100. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00365.x.","journal-title":"Kidney Int"},{"key":"3045_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"key":"3045_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/joim.13279","volume":"290","author":"AD Smith","year":"2021","unstructured":"Smith AD, Refsum H. Homocysteine - from disease biomarker to disease prevention. J Intern Med. 2021;290:826\u201354. https:\/\/doi.org\/10.1111\/joim.13279.","journal-title":"J Intern Med"},{"key":"3045_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s12272-018-1016-4","volume":"41","author":"J Kim","year":"2018","unstructured":"Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Arch Pharm Res. 2018;41:372\u201383. https:\/\/doi.org\/10.1007\/s12272-018-1016-4.","journal-title":"Arch Pharm Res"},{"key":"3045_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12882-021-02632-3","volume":"23","author":"Z Li","year":"2022","unstructured":"Li Z, Han Q, Ye H, et al. Serum homocysteine is associated with tubular interstitial lesions at the early stage of IgA nephropathy. BMC Nephrol. 2022;23:78. https:\/\/doi.org\/10.1186\/s12882-021-02632-3.","journal-title":"BMC Nephrol"},{"key":"3045_CR16","doi-asserted-by":"publisher","first-page":"812552","DOI":"10.3389\/fmed.2022.812552","volume":"9","author":"YN Wang","year":"2022","unstructured":"Wang YN, Xia H, Song ZR, Zhou XJ, Zhang H. Plasma homocysteine as a potential marker of early renal function decline in IgA nephropathy. Front Med. 2022;9:812552. https:\/\/doi.org\/10.3389\/fmed.2022.812552.","journal-title":"Front Med"},{"key":"3045_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/ndt\/gfv380","volume":"31","author":"JD Spence","year":"2016","unstructured":"Spence JD, Urquhart BL, Bang H. Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine. Nephrol Dial Transplant. 2016;31:937\u201344. https:\/\/doi.org\/10.1093\/ndt\/gfv380.","journal-title":"Nephrol Dial Transplant"},{"key":"3045_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.acc.2015.07.002","volume":"72","author":"EA Ostrakhovitch","year":"2015","unstructured":"Ostrakhovitch EA, Tabibzadeh S. Homocysteine in chronic kidney disease. Adv Clin Chem. 2015;72:77\u2013106. https:\/\/doi.org\/10.1016\/bs.acc.2015.07.002.","journal-title":"Adv Clin Chem"},{"key":"3045_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.bjp.0702374","volume":"126","author":"AM Emsley","year":"1999","unstructured":"Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol. 1999;126:1034\u201340. https:\/\/doi.org\/10.1038\/sj.bjp.0702374.","journal-title":"Br J Pharmacol"},{"key":"3045_CR20","doi-asserted-by":"publisher","first-page":"3256325","DOI":"10.1155\/2017\/3256325","volume":"2017","author":"MF Zhong","year":"2017","unstructured":"Zhong MF, Zhao YH, Xu H, Tan X, Wang YK, Wang WZ. The cardiovascular effect of systemic homocysteine is associated with oxidative stress in the rostral ventrolateral medulla. Neural Plast. 2017;2017:3256325. https:\/\/doi.org\/10.1155\/2017\/3256325.","journal-title":"Neural Plast"},{"key":"3045_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000514360","volume":"46","author":"W Xiao","year":"2021","unstructured":"Xiao W, Ye P, Wang F, Cao R, Bai Y, Wang X. Plasma homocysteine is a predictive factor for accelerated renal function decline and chronic kidney disease in a community-dwelling population. Kidney Blood Press Res. 2021;46:541\u20139. https:\/\/doi.org\/10.1159\/000514360.","journal-title":"Kidney Blood Press Res"},{"key":"3045_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40620-019-00622-1","volume":"32","author":"AF Perna","year":"2019","unstructured":"Perna AF, Ingrosso D. Homocysteine and chronic kidney disease: an ongoing narrative. J Nephrol. 2019;32:673\u20135. https:\/\/doi.org\/10.1007\/s40620-019-00622-1.","journal-title":"J Nephrol"},{"key":"3045_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cca.2014.02.007","volume":"431","author":"S Mao","year":"2014","unstructured":"Mao S, Xiang W, Huang S, Zhang A. Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clin Chim Acta. 2014;431:206\u201310. https:\/\/doi.org\/10.1016\/j.cca.2014.02.007.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"3045_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/nu8100665","volume":"8","author":"C Cai","year":"2016","unstructured":"Cai C, Xiao R, Van Halm-Lutterodt N, et al. Association of MTHFR, SLC19A1 genetic polymorphism, serum folate, vitamin B12 and Hcy status with cognitive functions in Chinese adults. Nutrients. 2016;8(10):665. https:\/\/doi.org\/10.3390\/nu8100665.","journal-title":"Nutrients."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03045-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-03045-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03045-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T14:54:42Z","timestamp":1672757682000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-03045-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3045"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-03045-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1914108\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the National Center for Health Statistics Research Ethics Review Board. Written informed consent was obtained from all participants for their participation in this study. The study protocol was performed in accordance with performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"419"}}